Related Experiment Video

Updated: Jul 17, 2026

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model
09:31

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Published on: October 2, 2015

Mitoxantrone in malignant pleural mesothelioma: a study by the EORTC Lung Cancer Cooperative Group

F J van Breukelen1, K Mattson, G Giaccone

  • 1Spaarne Ziekenhuis, Haarlem, The Netherlands.

European Journal of Cancer (Oxford, England : 1990)
|January 1, 1991
PubMed

Insights

This phase II study investigated mitoxantrone for malignant pleural mesothelioma. The chemotherapy showed marginal activity, with only one partial response observed in 34 evaluated patients.

Area of Science:

  • Oncology
  • Medical Research

Background:

  • Malignant pleural mesothelioma is a rare and aggressive cancer.
  • Effective chemotherapy options for this condition are limited.

Purpose of the Study:

  • To evaluate the efficacy and toxicity of mitoxantrone in patients with malignant pleural mesothelioma.

Main Methods:

  • A phase II clinical trial was conducted involving 46 patients.
  • Patients received mitoxantrone at a dose of 14 mg/m2 every 3 weeks.
  • Histological confirmation and prior chemotherapy status were assessed.

Main Results:

  • 34 patients were evaluated for response.
  • Only one partial response was recorded.
  • Toxicity was primarily mild gastrointestinal and hematological side effects.

Conclusions:

  • Mitoxantrone, at the tested dose and schedule, demonstrates marginal activity against malignant pleural mesothelioma.
  • Further research may be needed to explore alternative treatments or combinations.

More Related Videos

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice07:54

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice

Published on: December 21, 2019

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...